Author: admin

Home / admin
Satish Shah, MD, our Medical Director, speaks about Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors.
Post

Satish Shah, MD, our Medical Director, speaks about Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors.

Satish Shah, MD, Medical Director, Gettysburg Cancer Center speaks about Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors.   Watch Video   Link to Article: http://www.globenewswire.com/news-release/2021/03/24/2198364/0/en/Theratechnologies-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-TH1902-for-Sortilin-Positive-Solid-Tumors.html Theratechnologies Inc., a biopharmaceutical company focusing on the discovery and commercialization of novel therapies, is pleased to report that the...

Gettysburg Cancer Center (GCC) has administered the first dose of a new, innovative cancer therapy ever given to a human being anywhere in the world
Post

Gettysburg Cancer Center (GCC) has administered the first dose of a new, innovative cancer therapy ever given to a human being anywhere in the world

This news release is an announcement that the Gettysburg Cancer Center (GCC) has administered the first dose of a new, innovative cancer therapy ever given to a human being anywhere in the world. This is a testament to the dedication and hard work of the doctors and staff of GCC to ensure that Gettysburg and...

Study of TH1902 in Patients with Advanced Solid Tumors and Expansion
Post

Study of TH1902 in Patients with Advanced Solid Tumors and Expansion

A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients with Advanced Solid Tumors and Expansion in Patients with Triple Negative Breast Cancer, Gynecological Cancer, Colorectal cancer, and Pancreatic Cancer. Even though this study is a Phase 1 it received FDA Fast Track Approval on February 4, 2021. An excerpt from the News Release...

Trilaciclib Prior to Myelosuppressive Chemo Reduces Need for Supportive Care in Small Cell Lung Cancer
Post

Trilaciclib Prior to Myelosuppressive Chemo Reduces Need for Supportive Care in Small Cell Lung Cancer

December 9, 2020 – Hayley Virgil Renata Ferrarotto, MD, discusses trilaciclib’s unique mechanism of action in small cell lung cancer and the data that led to its FDA designation. Trilaciclib administered prior to chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) helped to reduce chemotherapy-induced myelosuppression and limit the need for granulocyte colony-stimulating factors...

Should Cancer Patients Get the COVID-19 Vaccine?
Post

Should Cancer Patients Get the COVID-19 Vaccine?

Microsoft Word – Document1 Reviewed by UPMC Hillman Cancer Center January 4, 2021 In December 2020, health care workers and residents of long-term care facilities began receiving newly authorized COVID-19 vaccines. This made them some of the first in line for life-saving vaccinations developed at unprecedented speed. People with underlying health issues are next in...

COVID-19 Vaccine and Lung Cancer: Top 10 Questions Answered
Post

COVID-19 Vaccine and Lung Cancer: Top 10 Questions Answered

Posted on January 19, 2021 – 12:58pm LUNGevity Foundation This information has been reviewed and endorsed by members of LUNGevity Foundation’s Scientific Advisory Board. Who should receive the COVID-19 vaccine?  We recommend the COVID-19 vaccine for virtually all lung cancer patients, with the exception of those with a known severe reaction to polyethylene glycol or polysorbate. Medical and...

Similarities in Risk for COVID-19 and Cancer Disparities
Post

Similarities in Risk for COVID-19 and Cancer Disparities

Lisa A. Newman, Robert A. Winn and John M. Carethers DOI: 10.1158/1078-0432.CCR-20-3421 Published January 2021 Abstract Coronavirus disease 2019 (COVID-19) is a novel infectious disease that has spread worldwide. In the United States, COVID-19 disproportionately affects racial and ethnic minorities, particularly African Americans, with an observed 2-fold higher rate for hospitalization and greater than 2-fold higher rate for death as compared with White Americans....

COVID-19 Resources
Post

COVID-19 Resources

The Gettysburg Cancer Center wants to continue keeping our patients informed with all the latest updates surrounding the Coronavirus Pandemic. Most people who are infected with COVID-19 will experience mild to moderate respiratory problems and recover without requiring special treatment. However, people who have an underlying medical condition like cancer, could develop more advanced health...

  • 1
  • 2
  • 8